Braveheart Bio, Inc.
corporate_fare Company Profile
Braveheart Bio, Inc. (NASDAQ:BRVE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for BRVE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for BRVE spans 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- Braveheart Bio Reports Q2 2026 Results, Initiates Phase 3 LIONHEART-HCM Trial, Extends Cash Runway to 2029
- Andreessen Horowitz Discloses 11.4% Stake in Braveheart Bio with Registration Rights
- Andreessen Horowitz Fund Bought $19.8M in Braveheart Bio IPO, Converted $228.4M Preferred Stake
- OrbiMed Entities Buy $34.9M in Braveheart Bio IPO, Convert $228M Preferred Stake
- Forbion Entities Invest $64.8M in Braveheart Bio IPO and Convert Preferred Stock
Dilution Risk
Low riskFiling-implied dilution signals for BRVE, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
IPO Pricing Confirmed · Underwriters' Option
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →